2 Top Biotech Stocks to Buy in December
Your immune system is constantly working to clean up faulty cells and damaged tissues. It's working, right now, to mop up pathogenic microbes and cancer cells before they can gain a foothold in your body. The search-and-destroy capabilities of immune cells have long made them ideal candidates for novel medical interventions, but we've only recently gained enough control over biology to make it a reality.
Two biopharma companies eager to take advantage of the potential of cellular medicines are Iovance Biotherapeutics (NASDAQ: IOVA) and Fate Therapeutics (NASDAQ: FATE). Each is working on unique cell types in specific types of cancer, but recent and upcoming data readouts make these two of the top biotech stocks to buy in December.
Image source: Getty Images.
Source Fool.com
